Trial Profile

A phase 3 clinical study of ACI-24 (ACI-24.060)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 May 2024 New trial record
14 May 2024 According to an AC Immune media release, Takeda and AC Immune SA announced an exclusive, worldwide option and license agreement for AC Immune's active immunotherapies, including ACI-24.060 for the treatment of Alzheimer's disease. Takeda would conduct and fund all further clinical development and be responsible for all global regulatory activities.
14 May 2024 According to an AC Immune media release, impact of ACI-24.060 realized by partnering with Takeda, which will help company to move rapidly into Phase 3.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com